NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

RPP decision paper

Review of TA305; Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion

Final recommendation post consultation
The guidance should be transferred to the 'static guidance list'

1. Background

This guidance was issued in February 2014.

At the GE meeting of 14 February 2017 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

2. Proposal put to consultees and commentators

The guidance should be transferred to the 'static guidance list'.

3. Rationale for selecting this proposal

Since the publication of TA305, no significant new evidence has been identified that is likely to lead to a change in the current guidance.

4. Summary of consultee and commentator responses

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

Respondent: Bayer **Response to proposal:** Agree We agree with the proposal to move the topic to the static list and are not aware of any new data which would affect the decision in the proposal.	**Comment from Technology Appraisals** This comment has been noted.

Respondent: The Royal College of Ophthalmologists **Response to proposal:** Agree The College is supportive of the move until new evidence is made available. We expect new data in last quarter of 2018 or first quarter of 2019.	**Comment from Technology Appraisals** This comment has been noted.

Paper signed off by: Melinda Goodall, 7th April 2017

Contributors to this paper:

Technical Lead: Henry Edwards

Project Manager: Samantha Shannon